靶区边距与同步放化疗治疗非小细胞肺癌的局部区域控制及急性毒性的关联
本研究回顾了2009至2016年间82例接受同步放化疗的不可手术非小细胞肺癌患者的记录,以边距偏差指数(MDI)量化靶区边距变化,按MDI上三分位值5.8%将患者二分类。结果显示MDI≥5.8%与局部区域进展风险无显著差异(校正HR 0.88,P=.76),但与≥3级放射性食管炎或放射性肺炎风险降低相关(校正HR 0.27,P=.027)。作者认为较小边距用于较大肿瘤未增加局部区域失败,需进一步研究明确较小边距联合现代放疗技术是否降低治疗相关毒性。
要点
- MDI≥5.8%组与<5.8%组的局部区域进展风险无显著差异(校正HR 0.88,P=.76)。
- MDI≥5.8%组≥3级放射性食管炎或放射性肺炎风险降低(校正HR 0.27,P=.027)。
- MDI≥5.8%组临床靶区+计划靶区边距中位5.6 mm vs 8 mm(P<.0001)。
核心结论
- 较小边距用于较大肿瘤未伴随局部区域失败增加,额外研究可明确较小边距联合现代放疗技术是否降低不可手术非小细胞肺癌的治疗相关毒性。
研究设计与样本
- 回顾性分析2009至2016年间82例接受同步放化疗的不可手术非小细胞肺癌患者记录,所有患者接受基于正电子发射断层扫描的治疗计划、4维计算机断层扫描模拟定义内靶区及每日锥形束计算机断层扫描。
- 以边距偏差指数(MDI)量化靶区边距变化,MDI为原始计划靶区与超出原始大体肿瘤体积10 mm的标准参考计划靶区之间等效均匀剂量的百分比变化,较大MDI等同于较小有效靶区边距。
- 按MDI上三分位值5.8%将患者二分类,终点包括至局部区域进展时间和至≥3级放射性食管炎或放射性肺炎时间,采用Fine-Gray方法建模。
主要发现
- 中位随访37.8个月(范围5.9-58.1个月)。
- 较大MDI与较小临床靶区+计划靶区边距、较大大体肿瘤体积、较晚治疗年份及调强放疗使用相关。
- MDI≥5.8% vs <5.8%的局部区域进展风险无显著差异(校正风险比0.88;P=.76)。
- MDI≥5.8%组≥3级放射性食管炎或放射性肺炎风险降低(校正风险比0.27;P=.027)。
- MDI≥5.8%组临床靶区+计划靶区边距中位5.6 mm vs 8 mm(P<.0001),食管接受≥50 Gy体积中位31.1% vs 35.3%(P=.069)。
关键数值与推荐
- MDI计算为原始计划靶区与超出原始大体肿瘤体积10 mm的标准参考计划靶区之间等效均匀剂量的百分比变化。
- 按MDI上三分位值5.8%二分类患者。
- 局部区域进展校正风险比0.88(P=.76),≥3级放射性食管炎或放射性肺炎校正风险比0.27(P=.027)。
- 临床靶区+计划靶区边距中位5.6 mm vs 8 mm(P<.0001),食管接受≥50 Gy体积中位31.1% vs 35.3%(P=.069)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to investigate the association between target volume margins and clinical outcomes for patients with inoperable non-small cell lung cancer (NSCLC) treated with concurrent chemoradiation therapy. METHODS AND MATERIALS: We reviewed the records of 82 patients with inoperable NSCLC treated between 2009 and 2016 with concurrent chemoradiation. All patients received positron emission tomography-based treatment planning, 4-dimensional computed tomography simulation to define an internal target volume, and daily cone beam computed tomography. We quantified variations in target volume margins with a margin deviation index (MDI), calculated as the percentage change in equivalent uniform dose between the original planning target volume (PTV) and a standard reference PTV 10 mm beyond the original gross tumor volume, consistent with the minimum margins mandated by recent NSCLC trials. Greater MDIs equated to smaller effective target volume margins. We dichotomized patients by the upper tercile MDI value (5.8%). Endpoints included time to locoregional progression and time to grade ≥ 3 radiation esophagitis (RE3) or radiation pneumonitis (RP3), modelled with the Fine-Gray method. RESULTS: Median follow-up was 37.8 months (range, 5.9-58.1 months). Larger MDIs correlated with smaller clinical target volume (CTV) + PTV margins, larger gross tumor volumes, later treatment year, and intensity modulated radiation therapy use. The risk of locoregional progression did not differ for MDI ≥5.8% versus <5.8% (adjusted hazard ratio: 0.88; P = .76), but the risk of RE3 or RP3 was decreased for MDI ≥5.8% (adjusted hazard ratio: 0.27; P = .027). Patients with MDI ≥5.8% were treated with smaller CTV + PTV margins (median, 5.6 vs 8 mm; P < .0001) and a marginally lower volume of esophagus receiving ≥50 Gy (median, 31.1% vs 35.3%; P = .069). CONCLUSIONS: Smaller margins were used for larger tumors but were not associated with an increase in locoregional failures. Additional studies could clarify whether smaller margins, when used alongside modern radiation therapy techniques, decrease treatment-related toxicity for inoperable NSCLC.
引用
- Yegya-Raman N, Reyhan M, Kim S, et al. Association of Target Volume Margins With Locoregional Control and Acute Toxicities for Non-small cell lung cancer Treated With Concurrent Chemoradiation Therapy. Pract Radiat Oncol. 2018. PMID: 30144583. doi:10.1016/j.prro.2018.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。